 Home > Active Ingredient News > Antitumor Therapy > Liver Cancer: The efficacy of Camrelizumab in the treatment of advanced hepatocellular carcinoma (HCC) patients with previous treatment progression: an update on the long-term follow-up results of the Phase 2 clinical study

Liver Cancer: The efficacy of Camrelizumab in the treatment of advanced hepatocellular carcinoma (HCC) patients with previous treatment progression: an update on the long-term follow-up results of the Phase 2 clinical study

 Last Update: 2021-08-01
 Source: Internet
 Author: User

Tags

mms treatment

curaderm treatment pictures

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The development of immunotherapy provides more treatment options for patients with advanced hepatocellular carcinoma (HCC)

Camrelizumab is a PD-1 inhibitor independently developed by China

From November 15, 2016 to November 16, 2017, a total of 217 patients were enrolled and received at least one course of camrelizumab: 109 of them were in the 2-week group and 108 were in the 3-week group

As of data cut-off, 146 (67.

Among 172 patients (79.

Among the 102 patients in the TBP group, 24 patients had tumor shrinkage greater than 30% compared to baseline, median OS did not reach (95% CI 19.

OS in TBP and non-TBP groups

Among 217 patients, 198 (91.

Adverse events

In summary, long-term follow-up has further confirmed that Camrelizumab can improve the prognosis of advanced hepatocellular carcinoma (HCC) patients who have progressed in previous treatments
.
For patients whose progress of carrelizumab treatment is assessed for the first time (RECIST criteria), continuing carrelizumab still has a survival benefit
.
Long-term follow-up has further confirmed that Camrelizumab can improve the prognosis of advanced hepatocellular carcinoma (HCC) patients whose previous treatment has progressed
.
For patients whose progress of carrelizumab treatment is assessed for the first time (RECIST criteria), continuing carrelizumab still has a survival benefit
.
Long-term follow-up has further confirmed that Camrelizumab can improve the prognosis of advanced hepatocellular carcinoma (HCC) patients whose previous treatment has progressed
.
For patients whose progress of carrelizumab treatment is assessed for the first time (RECIST criteria), continuing carrelizumab still has a survival benefit
.

Original source:

Zhenggang Ren, Shukui Qin, Zhiqiang Meng, et al.
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression.
Liver Cancer.
DOI: 10.
1159/000516470.
Published online: June 30, 2021.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.